United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
The Pharma Data
OCTOBER 27, 2020
License-related fees (5). License-related fees (5). The BREEZE study (NCT03950739) seeks to evaluate 45 patients on a stable dose of Tyvaso after switching to our new dry powder inhaler (DPI) form of treprostinil, which we licensed from MannKind Corporation. .
40 
Let's personalize your content